Biomea Fusion (BMEA) Profit After Tax (2020 - 2026)
Biomea Fusion (BMEA) posted Profit After Tax of -$12.4 million for Q1 2026, down 369.19% sequentially from $4.6 million in Q4 2025, and up 57.57% YoY from -$7.9 million in Q1 2025.
Biomea Fusion (BMEA) Profit After Tax (2020 - 2026) Analysis & Trends
Biomea Fusion has reported Profit After Tax for 7 years, with the latest figure at -$12.4 million in Q1 2026.
- Quarterly Profit After Tax rose 57.57% year-over-year to -$12.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.9 million (up 65.05% YoY) and the FY2025 annual result came in at -$61.8 million, up 55.36% from the prior year.
- Profit After Tax declined to -$12.4 million in Q1 2026 per BMEA's latest filing, from $4.6 million in the prior quarter.
- Over five years, Profit After Tax peaked at $4.6 million in Q4 2025 and troughed at -$39.1 million in Q1 2024.
- A 5-year average of -$24.2 million and a median of -$25.3 million in 2022 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax plunged 179.67% in 2022, then jumped 115.74% in 2025.
- Over 5 years, Profit After Tax stood at -$25.3 million in 2022, then plunged by 37.81% to -$34.9 million in 2023, then increased by 16.0% to -$29.3 million in 2024, then surged by 115.74% to $4.6 million in 2025, then tumbled by 369.19% to -$12.4 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$12.4 million, $4.6 million, and -$16.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | -8.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.33 Mn |
| Mar 31, 2026 | -12.42 Mn |
| Dec 31, 2025 | 4.61 Mn |
| Sep 30, 2025 | -16.41 Mn |
| Jun 30, 2025 | -20.74 Mn |
| Mar 31, 2025 | -29.26 Mn |
| Dec 31, 2024 | -29.30 Mn |
| Sep 30, 2024 | -32.79 Mn |
| Jun 30, 2024 | -37.28 Mn |
| Mar 31, 2024 | -39.06 Mn |
| Dec 31, 2023 | -34.88 Mn |
| Sep 30, 2023 | -28.43 Mn |
| Jun 30, 2023 | -24.89 Mn |
| Mar 31, 2023 | -29.05 Mn |
| Dec 31, 2022 | -25.31 Mn |
| Sep 30, 2022 | -22.89 Mn |
| Jun 30, 2022 | -17.26 Mn |
| Mar 31, 2022 | -16.37 Mn |
| Dec 31, 2021 | -14.71 Mn |
| Sep 30, 2021 | -12.61 Mn |